NanoViricides Inc. (NNVC)

[Doctor_Hari_Seldon]

NEWS NNVC 23NOV2009 paraphrase from information provided through WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) … FluCide™ animal study clearly established that the new version of FluCide™ is superior to the older version. The data also showed extremely large survival lifetime improvement compared to an extended therapy using oseltamivir (Tamiflu® Roche)…a technology that mimics natural and conserved binding sites of the viruses. This allows rapid development. Also, it means that a virus is far less likely to escape a nanoviricide compared to its escape rate against a highly specific drug discovered using a conventional methodology…study of FluCide was conducted using the same total lethality protocol employed in previous influenza studies by the Company…the new version of FluCide drug candidate extended the lifespan of lethally infected mice to 334±11 hrs (or 14 days) on average..in contrast, mice treated with an extended oseltamivir protocol survived for 193±3 hrs (or 8 days) on average…with control infected mice surviving only 121±2 hrs (or 5 days)…one million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice with repeat “booster” infection performed at 22 hrs. Being a highly lethal model survival lifetimes can be directly used for rank ordering of efficacy of drug candidates…analysis of the data from additional parameters is anticpated…a previous version of the FluCide drug candidate was highly effective against two different clades of the H5N1 bird flu virus, in addition to being highly effective against H1N1 in the mouse model..a recently improved the FluCide drug candidate creates what it believed to be a single drug candidate against all forms of influenza. The Company believes that the data presented at the Influenza Conference establish this pan-influenza drug candidate as a leading anti-influenza drug in development…